Oncogènesi i drogues antitumorals

  • Mangues Group 2021


Our work focuses on the preclinical development of nanomedicines, which include protein-based self-assembled nanoparticles, and drug-nanoparticle conjugates, for therapy of solid tumors and hematological neoplasias.

All developments pursue their clinical translation and their transfer to the Biotech and Pharma industry. We especially target cancer stem cells that overexpress the chemokine receptor CXCR4, using a targeted drug delivery approach that selectively eliminates these cells, leading to a blockade of metastatic dissemination. Depending on the tumor type, we chemically conjugate small drugs or toxins, or incorporate cytotoxic polypeptides as payloads, to the protein nanocarrier. Using this strategy, we have demonstrated potent prevention of metastasis development and regression of established metastases in colorectal cancer models. We also demonstrated a potent blockade of dissemination in acute myeloid leukemia and diffuse large B-cell lymphoma models.


- Professor Antonio Villaverde, Nanobiotechnology Group. Department of Genetics and Applied Microbiology, Autonomous University of Barcelona


Ramon ManguesRamon Mangues 2021Group Leader
Isolda CasanovaSenior Researcher
Ugutz UnzuetaSenior Researcher
Patricia ÁlamoPostdoctoral Researcher
Lorena AlbaPostdoctoral Researcher
Victor PallarèsPostdoctoral Researcher
Rita SalaPhD Student
Aïda FalgàsPhD Student
Esperanza MedinaPhD Student
Elisa RiojaPhD Student
Yaiza NúñezPhD Student
Luis Miguel CarrascoPhD Student
Annabel GarcíaTechnician
Carlos NavasTechnician

Current projects

Targeted Nanoparticle Combination for the Selective Kiling of Metastasis Stem Cells

Responsable:Ramon Mangues
Data d'inici:01/01/2019
Data de finalització:31/12/2021

Targeted nanocongugates for the selective elimination of stem cells in disseminated

Responsable:Ramon Mangues
Data d'inici:01/01/2016
Data de finalització:30/06/2020

Desarrollo de un nuevo medicamento selectivo con potente actividad antimetástatica (Nanotrac)

Responsable:Ramon Mangues
Data d'inici:01/01/2018
Data de finalització:30/06/2021

Cancer Nanomedicine. From bench to bedsiteCA17140

Responsable:Ramon Mangues
Data d'inici:01/01/2019
Data de finalització:30/12/2022

Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy

Responsable:Jordi Sierra
Data d'inici:01/04/2021
Data de finalització:30/03/2024